Medical Advocates
Entecavir (Baraclude/BMS-200475)
 
Journal Citations

General Reports
Pharmacokinetics
Drug/Drug Interactions
 Resistance
 Efficacy
Economics




 
Entecavir Main Page Main New/Newsworthy Home Page      
Last Update:  September 23, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
     Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT PDF ARTICLE
 Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic
hepatitis B patients
 You J, Sriplung H, Geater A, et al  
BMC Infect Dis. 2008 Sep 22;8(1):123.
 Paper
 
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and
lamivudine-naive patients.
 Sasadeusz J, Audsley J, Mijch A, et al
AIDS. 2008 May 11;22(8):947-55.
Abstract 
 
FULL-TEXT ARTICLE
 Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B.
 Lu GF, Tang FA, Zheng PY, et al 
World J Gastroenterol. 2008 Mar 14;14(10):1617-21.
 Abstract 

Entecavir Exhibits Inhibitory Activity Against HIV Under Conditions of Reduced Viral Challenge.
Lin PF, Nowicka-Sans B, Terry B, et al
Antimicrob Agents Chemother.
2008 Mar 3
 Abstract 

Entecavir for chronic hepatitis B: a review.
 Palumbo E.  
Ther Drug Monit. 2008 Feb;30(1):1-4.
 Abstract 
 
Entecavir: A new nucleoside analogue for the treatment of chronic hepatitis B.
 Rivkin A.
Drugs Today (Barc). 2007 Apr;43(4):201-20.
 Abstract 
Inhibition of Hepatitis B Virus Polymerase by Entecavir.
 Langley DR, Walsh AW, Baldick CJ, et al
J Virol. 2007 Jan 31;
 Abstract 
 
Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
 Sims KA, Woodland AM.  
Pharmacotherapy. 2006 Dec;26(12):1745-57.
Abstract 

Entecavir for the treatment of chronic hepatitis B.
 Shaw T, Locarnini S.
 Expert Rev Anti Infect Ther. 2004 Dec;2(6):853-71
 Abstract 

A WEEK-IN-REVIEW FEATURED REPORT
Entecavir: a potent new antiviral drug for hepatitis B.
Honkoop P, De Man RA.
 Expert Opin Investig Drugs. 2003 Apr;12(4):683-8.
 Abstract
 
Pharmacokinetics
     
     Journal Papers, Abstracts, and Commentaries
 
 
Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir
in hepatitis B virus-infected patients.
Zhu M, Bifano M, Xu X, et al  
Antimicrob Agents Chemother. 2008 Aug;52(8):2836-41.
Abstract
 
Lack of an Effect of HIV Co-Infection on the Pharmacokinetics of Entecavir in HBV Infected
Patients.
 Zhu M, Bifano M, Xu X, et al
Antimicrob Agents Chemother. 2008 Apr 7
 Abstract
 
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus
infected patient.
 Villet S, Ollivet A, Pichoud C, et al 
J Hepatol. 2006 Dec 18;
 Abstract

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in
healthy subjects.
 Yan JH, Bifano M, Olsen S, et al 
J Clin Pharmacol. 2006 Nov;46(11):1250-8.
 Abstract 

  
Drug/Drug Interactions
     
     Journal Papers, Abstracts, and Commentaries
 
 
Absence of a Pharmacokinetic Interaction Between Entecavir and Adefovir.
 Bifano M, Yan JH, Smith RA. et al
J Clin Pharmacol. 2007 Aug 3;
 Abstract
 
Resistance
 
     Journal Papers, Abstracts, and Commentaries
 
 
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with
entecavir resistance.
Baldick CJ, Tenney DJ, Mazzucco CE,et al
Hepatology. 2008 May;47(5):1473-82.
 Abstract 
 
Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral
therapy-naive patient.J
 Jakobsen MR, Arildsen H, Krarup HB, et al
Clin Infect Dis. 2008 May 1;46(9):e88-91.
 Abstract 
 
Hepatitis B virus polymerase variants associated with entecavir drug resistance in
treatment-naive patients.
Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, et al
J Viral Hepat. 2007 Dec;14(12):835-40.
 Abstract 
 
The HBV drug entecavir - effects on HIV-1 replication and resistance.
McMahon MA, Jilek BL, Brennan TP,
N Engl J Med. 2007 Jun 21;356(25):2614-21.
Abstract 
 
Two Year Entecavir Resistance Assessment in Lamivudine Refractory HBV Patients
Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present.
 Tenney DJ, Rose RE, Baldick CJ, et al 
Antimicrob Agents Chemother. 2006 Dec 18
 Abstract 
 
Entecavir resistance is rare in nucleoside naive patients with hepatitis B.
 Colonno RJ, Rose R, Baldick CJ, et al  
Hepatology. 2006 Dec;44(6):1656-65.
 Abstract 

FULL-TEXT ARTICLE
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions
in virus already resistant to Lamivudine.
Tenney DJ, Levine SM, Rose RE, et al
Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.
Paper

  
Efficacy
 
HBV

    Journal Papers, Abstracts, and Commentaries

 
Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis
or Cirrhosis.
Schiff E, Simsek H, Lee WM, et al
Am J Gastroenterol. 2008 Aug 21.
 Abstract
 
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.
Kamar N, Milioto O, Alric L, et al   
Transplantation. 2008 Aug 27;86(4):611-4
 Abstract
 
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B:
Randomized controlled trial in Japanese patients.
Suzuki F, Toyoda J, Katano Y, et al
J Gastroenterol Hepatol. 2008 Jun 12
 Abstract
 
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology
outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, et al
 Hepatology. 2008 Jul;48(1):99-108.
 Abstract
 
A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir
 Fukushima K, Ueno Y, Inoue J, et al 
Hepatol Res. 2008 May 20
 Abstract
 
The effect of entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its
relationship to HBeAg sero-conversion
Li JX.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Apr;22(2):122-3
 Abstract
 
FULL TEXT ARTICLE
 A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.
 Ren FY, Piao DM, Piao XX. 
World J Gastroenterol. 2007 Aug 21;13(31):4264-7.
Paper
 
Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom
lamivudine treatment failed is associated with efficacy at week 48
Ma H, Ren JB, Li HY, et al
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Jun;21(2):102-4
 Abstract
 
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B.
 Sherman M, Yurdaydin C, Sollano J, et al 
Gastroenterology. 2006 Jun;130(7):2039-49
 Abstract
 

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
 Chang TT, Gish RG, de Man R, Gadano A, et al  
N Engl J Med. 2006 Mar 9;354(10):1001-10.
 Abstract

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
 Lai CL, Shouval D, Lok AS, Chang TT,
N Engl J Med. 2006 Mar 9;354(10):1011-20.
 Abstract
 
 
HIV/HBV Coinfection
 
    Journal Papers, Abstracts, and Commentaries
 
 
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine
as part of antiretroviral therapy.
 Pessôa MG, Gazzard B, Huang AK, et al 
AIDS. 2008 Sep 12;22(14):1779-87.
 Abstract
 
A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir.
Fukushima K, Ueno Y, Inoue J,  et al  
Hepatol Res. 2008 Aug;38(8):842-6.
 Abstract

The anti-HIV antiviral activity of entecavir: The loss of a trusted friend?
 Sasadeusz J. 
J Hepatol. 2007 Oct 1;
 Abstract
Economics
     
     Journal Papers, Abstracts, and Commentaries
 
 
Pharmacoeconomics of entecavir treatment for chronic hepatitis B.
 You JH, Chan FW.  
Expert Opin Pharmacother. 2008 Oct;9(15):2673-81.
 Abstract
 
Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB)
patients in China from a perspective of the Chinese Social Security program.
 Yuan Y, Iloeje U, Li H,
Value Health. 2008 Mar;11 Suppl 1:S11-22
 Abstract
 
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive
chronic hepatitis B patients.
Yuan Y, Iloeje UH, Hay J, Saab S.
J Manag Care Pharm. 2008 Jan-Feb;14(1):21-33.L
 Abstract
 
 
Entecavir Main Page Main New/Newsworthy Home Page      

Entecavir Journal Citations